This process resulted in an increased susceptibility of BC cells to the action of anticancer agents and was mediated by the interaction of protein H2AX with E3 ubiquitine ligase RNF168, which led to proteasomal degradation of H2AX, thereby causing a stable reduction in H2AX in conditions of chronic oxidative stress. Here, H2AX is linked to breast cancer.